Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1980 1
1983 1
1984 1
1985 2
1987 2
1988 2
1989 4
1990 2
1991 2
1992 5
1993 3
1995 3
1996 1
1997 2
1998 9
1999 6
2000 2
2001 2
2002 15
2003 5
2004 7
2005 11
2006 13
2007 20
2008 19
2009 22
2010 29
2011 47
2012 65
2013 73
2014 69
2015 70
2016 68
2017 34
2018 44
2019 45
2020 31
2021 34
2022 34
2023 32
2024 24
2025 37
2026 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

789 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models.
Ren F, Aliper A, Chen J, Zhao H, Rao S, Kuppe C, Ozerov IV, Zhang M, Witte K, Kruse C, Aladinskiy V, Ivanenkov Y, Polykovskiy D, Fu Y, Babin E, Qiao J, Liang X, Mou Z, Wang H, Pun FW, Torres-Ayuso P, Veviorskiy A, Song D, Liu S, Zhang B, Naumov V, Ding X, Kukharenko A, Izumchenko E, Zhavoronkov A. Ren F, et al. Nat Biotechnol. 2025 Jan;43(1):63-75. doi: 10.1038/s41587-024-02143-0. Epub 2024 Mar 8. Nat Biotechnol. 2025. PMID: 38459338 Free PMC article. Clinical Trial.
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS.
Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barthélemy NR, Bateman RJ. Lucey BP, et al. Ann Neurol. 2023 Jul;94(1):27-40. doi: 10.1002/ana.26641. Epub 2023 Apr 20. Ann Neurol. 2023. PMID: 36897120 Free PMC article. Clinical Trial.
RESULTS: The ratio of phosphorylated-tau-threonine-181 to unphosphorylated-tau-threonine-181, a measure of phosphorylation at this tau phosphosite, decreased ~10% to 15% in participants treated with suvorexant 20 mg compared to placebo. However, phosphorylation at t …
RESULTS: The ratio of phosphorylated-tau-threonine-181 to unphosphorylated-tau-threonine-181, a measure of phosphorylation at …
mTOR inhibition improves immune function in the elderly.
Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB. Mannick JB, et al. Sci Transl Med. 2014 Dec 24;6(268):268ra179. doi: 10.1126/scitranslmed.3009892. Sci Transl Med. 2014. PMID: 25540326 Clinical Trial.
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.
DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, Dwyer S, Pan TC, Nivar I, Chen Y, Wileyto P, Berry LR, Deluca S, Savage J, Makhlin I, Pant DK, Martin H, Egunsola A, Mears N, Goodspeed BL, Chislock EM, Graves J, Wang J, Shih N, Belka GK, Berry D, Nayak A, Feldman M, Chodosh LA. DeMichele A, et al. Nat Med. 2025 Oct;31(10):3464-3474. doi: 10.1038/s41591-025-03877-3. Epub 2025 Sep 2. Nat Med. 2025. PMID: 40897974 Clinical Trial.
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Jennings D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, Chen JJ, Maciuca R, Fraser K, Mabrouk OS, van de Wetering de Rooij J, Heuberger JAAC, Groeneveld GJ, Borin MT, Cruz-Herranz A, Graham D, Scearce-Levie K, De Vicente J, Henry AG, Chin P, Ho C, Troyer MD. Jennings D, et al. Mov Disord. 2023 Mar;38(3):386-398. doi: 10.1002/mds.29297. Epub 2023 Feb 18. Mov Disord. 2023. PMID: 36807624 Clinical Trial.
Dose-dependent median reductions from baseline were observed in whole-blood phosphorylated serine 935 LRRK2 ( 98%), peripheral blood mononuclear cell phosphorylated threonine 73 pRab10 ( 93%), cerebrospinal fluid total LRRK2 ( 50%), and urine bis (monoacylglycerol) phospha …
Dose-dependent median reductions from baseline were observed in whole-blood phosphorylated serine 935 LRRK2 ( 98%), peripheral blood mononuc …
Threonine requirement of parenterally fed postsurgical human neonates.
Chapman KP, Courtney-Martin G, Moore AM, Ball RO, Pencharz PB. Chapman KP, et al. Am J Clin Nutr. 2009 Jan;89(1):134-41. doi: 10.3945/ajcn.2008.26654. Epub 2008 Dec 3. Am J Clin Nutr. 2009. PMID: 19056607 Free article. Clinical Trial.
Graded intakes of threonine had no effect on phenylalanine flux. CONCLUSION: This is the first study to report on the threonine requirement for human neonates receiving PN. We found that the threonine requirement for postsurgical PN-fed neonates is 22-32% of …
Graded intakes of threonine had no effect on phenylalanine flux. CONCLUSION: This is the first study to report on the threonine …
Evaluation of safe utilization of L-threonine for supplementation in healthy adults: a randomized double blind controlled trial.
Matsumoto H, Miura N, Naito M, Elango R. Matsumoto H, et al. Amino Acids. 2025 May 27;57(1):30. doi: 10.1007/s00726-025-03461-6. Amino Acids. 2025. PMID: 40419835 Free PMC article. Clinical Trial.
L-threonine is used in dietary supplements and nutritional products ingested by healthy consumers. ...Also, the concentration of L-threonine as well as the concentration of its metabolite L-2-amino butylate were found to be increased in plasma after supplementation …
L-threonine is used in dietary supplements and nutritional products ingested by healthy consumers. ...Also, the concentration of L- …
Threonine requirement of healthy adults, derived with a 24-h indicator amino acid balance technique.
Borgonha S, Regan MM, Oh SH, Condon M, Young VR. Borgonha S, et al. Am J Clin Nutr. 2002 Apr;75(4):698-704. doi: 10.1093/ajcn/75.4.698. Am J Clin Nutr. 2002. PMID: 11916756 Clinical Trial.
OBJECTIVE: Our goal was to assess threonine adequacy at 3 test intakes and the consequences of a 6-d compared with a 13-d dietary adaptation phase. DESIGN: We used a 24-h indicator amino acid balance technique ([1-(13)C]leucine as indicator) to assess the threonine …
OBJECTIVE: Our goal was to assess threonine adequacy at 3 test intakes and the consequences of a 6-d compared with a 13-d dietary ada …
Length of Adaptation Has No Effect on the Threonine Requirement Determined in Healthy Young Adult Males Using the Indicator Amino Acid Oxidation Method.
Szwiega S, Pencharz PB, Ball RO, Xu L, Kong D, Elango R, Courtney-Martin G. Szwiega S, et al. J Nutr. 2023 Jul;153(7):2016-2026. doi: 10.1016/j.tjnut.2023.03.033. Epub 2023 Mar 31. J Nutr. 2023. PMID: 37004875 Free article. Clinical Trial.
OBJECTIVES: The IAAO method was used to determine whether 3 or 7 d of adaptation to each threonine intake alters the threonine requirement in adult men compared to 1 d of adaptation. METHODS: Eleven healthy adult men (19-35 y, body mass index (BMI) 23.4 in kg m(-2)) …
OBJECTIVES: The IAAO method was used to determine whether 3 or 7 d of adaptation to each threonine intake alters the threonine …
Threonine requirements of healthy Indian men, measured by a 24-h indicator amino acid oxidation and balance technique.
Kurpad AV, Raj T, Regan MM, Vasudevan J, Caszo B, Nazareth D, Gnanou J, Young VR. Kurpad AV, et al. Am J Clin Nutr. 2002 Oct;76(4):789-97. doi: 10.1093/ajcn/76.4.789. Am J Clin Nutr. 2002. PMID: 12324292 Clinical Trial.
There was no significant effect of threonine intake on 24-h leucine flux. CONCLUSION: The results of the 24-h indicator amino acid oxidation and balance experiments indicate that the current FAO/WHO/UNU threonine recommendation of 7 mg x kg(-1) x d(-1) is inadequate …
There was no significant effect of threonine intake on 24-h leucine flux. CONCLUSION: The results of the 24-h indicator amino acid ox …
789 results